Moleculin Biotech Inc MBRX

US Biotechnology

$0.40 ▼ -60.78% ($-0.62)

🧊 52W Low ⬇️ Below Yest. Low 🔥 High Short Interest 🎈 Low Float 🗓️ Earnings Next Week

Open $0.88

Prev Close $1.02

Day Range $0.31 – $1.07

52W Range $0.31 – $18.25

Market Cap $5.44M

Beta 1.85

EPS (TTM) $-25.49

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2016-06-02
Shares Out.	7,070,000
Website	moleculin.com/ ↗
Phone	13026365400
Employees	17
Net Income	-$12.8M
Total Assets	$23.4M
Total Liabilities	$8.2M
Equity	$15.2M

About Moleculin Biotech Inc

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Moleculin Biotech Inc is a publicly traded company under the ticker symbol MBRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.